AP611A - Oral liquid compositions containing paroxetine resinate. - Google Patents

Oral liquid compositions containing paroxetine resinate. Download PDF

Info

Publication number
AP611A
AP611A APAP/P/1996/000839A AP9600839A AP611A AP 611 A AP611 A AP 611A AP 9600839 A AP9600839 A AP 9600839A AP 611 A AP611 A AP 611A
Authority
AP
ARIPO
Prior art keywords
pharmaceutical composition
paroxetine
depression
oral liquid
composition according
Prior art date
Application number
APAP/P/1996/000839A
Other languages
English (en)
Other versions
AP9600839A0 (en
Inventor
Graham Stanley Leonard
David Cooper
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9600839A0 publication Critical patent/AP9600839A0/xx
Application granted granted Critical
Publication of AP611A publication Critical patent/AP611A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1996/000839A 1994-02-03 1995-01-30 Oral liquid compositions containing paroxetine resinate. AP611A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation
PCT/EP1995/000319 WO1995020964A1 (en) 1994-02-03 1995-01-30 Oral liquid compositions containing paroxetine resinate

Publications (2)

Publication Number Publication Date
AP9600839A0 AP9600839A0 (en) 1996-07-31
AP611A true AP611A (en) 1997-09-03

Family

ID=10749765

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1996/000839A AP611A (en) 1994-02-03 1995-01-30 Oral liquid compositions containing paroxetine resinate.
APAP/P/1995/000715A AP536A (en) 1994-02-03 1995-02-01 Oral liquid compositions containing paroxetine resinate

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/1995/000715A AP536A (en) 1994-02-03 1995-02-01 Oral liquid compositions containing paroxetine resinate

Country Status (33)

Country Link
US (1) US5811436A (cs)
EP (1) EP0742715B1 (cs)
JP (1) JP4445590B2 (cs)
CN (1) CN1074922C (cs)
AP (2) AP611A (cs)
AT (1) ATE178489T1 (cs)
AU (1) AU682091B2 (cs)
BG (1) BG62843B1 (cs)
BR (1) BR9507055A (cs)
CA (1) CA2182593A1 (cs)
CZ (1) CZ285128B6 (cs)
DE (1) DE69508924T2 (cs)
DK (1) DK0742715T3 (cs)
DZ (1) DZ1850A1 (cs)
ES (1) ES2129806T3 (cs)
FI (1) FI118205B (cs)
GB (1) GB9402029D0 (cs)
GR (1) GR3030131T3 (cs)
HU (1) HUT75941A (cs)
IL (1) IL112521A (cs)
MA (1) MA23441A1 (cs)
MX (1) MX9603203A (cs)
MY (1) MY113036A (cs)
NO (1) NO307954B1 (cs)
NZ (1) NZ278891A (cs)
OA (1) OA10446A (cs)
PL (1) PL178331B1 (cs)
RO (1) RO116342B1 (cs)
RU (1) RU2136281C1 (cs)
SK (1) SK281214B6 (cs)
TW (1) TW436296B (cs)
WO (1) WO1995020964A1 (cs)
ZA (1) ZA95776B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
ES2155995T3 (es) * 1997-06-10 2001-06-01 Synthon Bv Compuestos de 4-fenilpiperidina.
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
US20040242497A1 (en) * 2001-08-09 2004-12-02 Barges Causeret Nathalie Claude Marianne Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科（北京）研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
WO2010150219A1 (en) * 2009-06-25 2010-12-29 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
PL2572717T3 (pl) 2010-05-19 2016-12-30 Kompozycja farmaceutyczna zawierająca solifenacynę
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
EP3917523B1 (en) 2019-02-01 2024-09-11 University of South Carolina Bicyclic pyridine compounds for use in treating cancer
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
GB2636182A (en) 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215233A1 (cs) * 1973-01-30 1974-08-23 Ferrosan As
WO1991013612A1 (en) * 1990-03-12 1991-09-19 Beecham Group Plc Composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215233A1 (cs) * 1973-01-30 1974-08-23 Ferrosan As
WO1991013612A1 (en) * 1990-03-12 1991-09-19 Beecham Group Plc Composition

Also Published As

Publication number Publication date
BR9507055A (pt) 1997-09-02
WO1995020964A1 (en) 1995-08-10
CN1074922C (zh) 2001-11-21
AP9500715A0 (en) 1995-04-30
PL315679A1 (en) 1996-11-25
EP0742715B1 (en) 1999-04-07
RO116342B1 (ro) 2001-01-30
NO963244D0 (no) 1996-08-02
NO963244L (no) 1996-08-02
FI118205B (fi) 2007-08-31
HK1012288A1 (en) 1999-07-30
DZ1850A1 (fr) 2002-02-17
AP536A (en) 1996-09-26
RU2136281C1 (ru) 1999-09-10
HU9602151D0 (en) 1996-09-30
GB9402029D0 (en) 1994-03-30
US5811436A (en) 1998-09-22
BG62843B1 (bg) 2000-09-29
MY113036A (en) 2001-11-30
MX9603203A (es) 1997-03-29
NZ278891A (en) 1998-01-26
JP4445590B2 (ja) 2010-04-07
NO307954B1 (no) 2000-06-26
DE69508924T2 (de) 1999-10-21
CN1140411A (zh) 1997-01-15
CZ285128B6 (cs) 1999-05-12
DK0742715T3 (da) 1999-10-18
CZ229396A3 (en) 1997-01-15
FI963051A0 (fi) 1996-08-01
AU682091B2 (en) 1997-09-18
AU1536895A (en) 1995-08-21
SK100496A3 (en) 1996-12-04
DE69508924D1 (de) 1999-05-12
EP0742715A1 (en) 1996-11-20
IL112521A (en) 1999-09-22
BG100763A (bg) 1997-03-31
FI963051L (fi) 1996-08-01
HUT75941A (en) 1997-05-28
IL112521A0 (en) 1995-05-26
ATE178489T1 (de) 1999-04-15
JPH09508402A (ja) 1997-08-26
ZA95776B (en) 1996-08-01
CA2182593A1 (en) 1995-08-10
TW436296B (en) 2001-05-28
GR3030131T3 (en) 1999-07-30
PL178331B1 (pl) 2000-04-28
AP9600839A0 (en) 1996-07-31
SK281214B6 (sk) 2001-01-18
ES2129806T3 (es) 1999-06-16
OA10446A (en) 2002-03-26
MA23441A1 (fr) 1995-10-01

Similar Documents

Publication Publication Date Title
AP611A (en) Oral liquid compositions containing paroxetine resinate.
TW303298B (cs)
CA1312286C (en) Pharmaceutical preparation containing metoprolol
CA2139505C (en) Precipitation of one or more active compounds in situ
WO1999002158A1 (fr) Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane
AU781828B2 (en) Dosing regimens for lasofoxifene
JPH07196492A (ja) 体重増加を抑制する、または体重減少を誘発するための医薬組成物
TWI286072B (en) Sleeping medicine formed by coating solid
AU2001232079B2 (en) Water dispersible formulation of paroxetine
KR20140076998A (ko) 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법
CA2017619C (en) Use of naftopidil for the therapy of dysuria in cases of benign prostatic hypertrophy
JP4138209B2 (ja) プラバスタチン含有組成物
WO2005023236A1 (en) Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions
HK1012288B (en) Oral liquid compositions containing paroxetine resinate
EP1572158A1 (en) A new oral immediated release dosage form
JPH03123730A (ja) ニルバジピン含有持続性錠剤
JPH0725769A (ja) アロプリノール医薬用液剤ならびにその製造法
JP2003137778A (ja) 医薬組成物及び医薬品
CN100435847C (zh) 含有难溶解性主药之持续释放配方
JP2008105969A (ja) 酒石酸ゾルピデム組成物
WO1999043327A1 (fr) Compositions antimicrobiennes a effet synergique, medicaments et remedes pour maladies digestives contenant ces compositions, leur procede de production et preparations associees
HK1084582A1 (zh) 稳定的口服固体药物组合物
HK1084582B (en) Stable solid medicinal composition for oral administration